vs

Side-by-side financial comparison of RAYONIER INC (RYN) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

VERACYTE, INC. is the larger business by last-quarter revenue ($140.6M vs $117.5M, roughly 1.2× RAYONIER INC). VERACYTE, INC. runs the higher net margin — 29.3% vs 22.1%, a 7.2% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs -81.9%). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs 1.7%).

Rayonier Inc., headquartered in Wildlight, Florida is a timberland real estate investment trust ("REIT") with assets located in softwood timber growing regions in the United States and New Zealand. Its core business segments are timber and real estate.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

RYN vs VCYT — Head-to-Head

Bigger by revenue
VCYT
VCYT
1.2× larger
VCYT
$140.6M
$117.5M
RYN
Growing faster (revenue YoY)
VCYT
VCYT
+100.5% gap
VCYT
18.5%
-81.9%
RYN
Higher net margin
VCYT
VCYT
7.2% more per $
VCYT
29.3%
22.1%
RYN
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
1.7%
RYN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RYN
RYN
VCYT
VCYT
Revenue
$117.5M
$140.6M
Net Profit
$25.9M
$41.1M
Gross Margin
41.9%
72.5%
Operating Margin
23.0%
26.4%
Net Margin
22.1%
29.3%
Revenue YoY
-81.9%
18.5%
Net Profit YoY
-92.1%
704.8%
EPS (diluted)
$0.14
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYN
RYN
VCYT
VCYT
Q4 25
$117.5M
$140.6M
Q3 25
$177.5M
$131.9M
Q2 25
$106.5M
$130.2M
Q1 25
$82.9M
$114.5M
Q4 24
$650.5M
$118.6M
Q3 24
$124.1M
$115.9M
Q2 24
$99.6M
$114.4M
Q1 24
$113.7M
$96.8M
Net Profit
RYN
RYN
VCYT
VCYT
Q4 25
$25.9M
$41.1M
Q3 25
$43.2M
$19.1M
Q2 25
$408.7M
$-980.0K
Q1 25
$-3.4M
$7.0M
Q4 24
$327.1M
$5.1M
Q3 24
$28.8M
$15.2M
Q2 24
$1.9M
$5.7M
Q1 24
$1.4M
$-1.9M
Gross Margin
RYN
RYN
VCYT
VCYT
Q4 25
41.9%
72.5%
Q3 25
32.9%
69.2%
Q2 25
29.7%
69.0%
Q1 25
21.7%
69.5%
Q4 24
53.8%
66.4%
Q3 24
30.4%
68.2%
Q2 24
25.4%
68.1%
Q1 24
24.3%
64.5%
Operating Margin
RYN
RYN
VCYT
VCYT
Q4 25
23.0%
26.4%
Q3 25
23.5%
17.4%
Q2 25
13.7%
-4.0%
Q1 25
0.1%
2.5%
Q4 24
47.7%
3.5%
Q3 24
15.2%
10.4%
Q2 24
4.6%
4.0%
Q1 24
7.6%
-4.8%
Net Margin
RYN
RYN
VCYT
VCYT
Q4 25
22.1%
29.3%
Q3 25
24.3%
14.5%
Q2 25
383.6%
-0.8%
Q1 25
-4.1%
6.2%
Q4 24
45.1%
4.3%
Q3 24
23.2%
13.1%
Q2 24
1.9%
5.0%
Q1 24
1.2%
-1.9%
EPS (diluted)
RYN
RYN
VCYT
VCYT
Q4 25
$0.14
$0.50
Q3 25
$0.28
$0.24
Q2 25
$2.63
$-0.01
Q1 25
$-0.02
$0.09
Q4 24
$2.18
$0.07
Q3 24
$0.19
$0.19
Q2 24
$0.01
$0.07
Q1 24
$0.01
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYN
RYN
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$842.9M
$362.6M
Total DebtLower is stronger
$845.3M
Stockholders' EquityBook value
$2.2B
$1.3B
Total Assets
$3.4B
$1.4B
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYN
RYN
VCYT
VCYT
Q4 25
$842.9M
$362.6M
Q3 25
$919.6M
$315.6M
Q2 25
$892.3M
$219.5M
Q1 25
$216.2M
$186.1M
Q4 24
$303.1M
$239.1M
Q3 24
$51.9M
$274.1M
Q2 24
$120.2M
$235.9M
Q1 24
$142.1M
$209.2M
Total Debt
RYN
RYN
VCYT
VCYT
Q4 25
$845.3M
Q3 25
$845.1M
Q2 25
$844.9M
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.3B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
RYN
RYN
VCYT
VCYT
Q4 25
$2.2B
$1.3B
Q3 25
$2.3B
$1.3B
Q2 25
$2.3B
$1.2B
Q1 25
$1.9B
$1.2B
Q4 24
$1.8B
$1.2B
Q3 24
$1.8B
$1.2B
Q2 24
$1.8B
$1.1B
Q1 24
$1.8B
$1.1B
Total Assets
RYN
RYN
VCYT
VCYT
Q4 25
$3.4B
$1.4B
Q3 25
$3.5B
$1.4B
Q2 25
$3.5B
$1.3B
Q1 25
$3.4B
$1.3B
Q4 24
$3.5B
$1.3B
Q3 24
$3.5B
$1.3B
Q2 24
$3.5B
$1.2B
Q1 24
$3.6B
$1.2B
Debt / Equity
RYN
RYN
VCYT
VCYT
Q4 25
0.38×
Q3 25
0.37×
Q2 25
0.37×
Q1 25
0.55×
Q4 24
0.59×
Q3 24
0.72×
Q2 24
0.75×
Q1 24
0.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYN
RYN
VCYT
VCYT
Operating Cash FlowLast quarter
$256.7M
$52.6M
Free Cash FlowOCF − Capex
$48.8M
FCF MarginFCF / Revenue
34.7%
Capex IntensityCapex / Revenue
2.7%
Cash ConversionOCF / Net Profit
9.91×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYN
RYN
VCYT
VCYT
Q4 25
$256.7M
$52.6M
Q3 25
$116.2M
$44.8M
Q2 25
$61.0M
$33.6M
Q1 25
$27.7M
$5.4M
Q4 24
$261.6M
$24.5M
Q3 24
$66.2M
$30.0M
Q2 24
$55.3M
$29.6M
Q1 24
$52.3M
$-9.0M
Free Cash Flow
RYN
RYN
VCYT
VCYT
Q4 25
$48.8M
Q3 25
$99.9M
$42.0M
Q2 25
$32.3M
Q1 25
$3.5M
Q4 24
$20.4M
Q3 24
$42.2M
$27.7M
Q2 24
$26.8M
Q1 24
$-11.1M
FCF Margin
RYN
RYN
VCYT
VCYT
Q4 25
34.7%
Q3 25
56.3%
31.8%
Q2 25
24.8%
Q1 25
3.1%
Q4 24
17.2%
Q3 24
34.0%
23.9%
Q2 24
23.4%
Q1 24
-11.5%
Capex Intensity
RYN
RYN
VCYT
VCYT
Q4 25
2.7%
Q3 25
9.2%
2.1%
Q2 25
1.0%
Q1 25
1.6%
Q4 24
3.5%
Q3 24
19.3%
1.9%
Q2 24
2.4%
Q1 24
2.2%
Cash Conversion
RYN
RYN
VCYT
VCYT
Q4 25
9.91×
1.28×
Q3 25
2.69×
2.34×
Q2 25
0.15×
Q1 25
0.76×
Q4 24
0.80×
4.80×
Q3 24
2.30×
1.98×
Q2 24
29.07×
5.16×
Q1 24
38.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RYN
RYN

Real Estate Segment$42.3M36%
Pacific Northwest Timber Segment$19.8M17%
Stumpage Pay As Cut$19.3M16%
Improved Development$14.8M13%
Nontimber$13.2M11%
License Revenue Primarily From Hunting$5.3M4%
Land Based Solutions$2.9M2%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons